Study to Evaluate the Effect of Micardis® / MicardisPlus® on Metabolic Parameters in Patients With Essential Hypertension and Diabetes Mellitus
Micardis® / MicardisPlus® Monitoring of Morning Hypertension and Metabolism II
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Age > 18 years
- Hypertension
- Diabetes mellitus
Exclusion Criteria:
- Age < 18 years
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Patients with hypertension and diabetes mellitus
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Change from Baseline in systolic blood pressure (SBP)
Time Frame: Baseline, after 6 months
|
Baseline, after 6 months
|
|
Change from Baseline in diastolic blood pressure (DBP)
Time Frame: Baseline, afterr 6 months
|
Baseline, afterr 6 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of patients with adverse events
Time Frame: up to 6 months
|
up to 6 months
|
|
|
Assessment of efficacy by investigator on a 6-point scale
Time Frame: after 6 months
|
after 6 months
|
|
|
Assessment of tolerability by investigator on a 5-point scale
Time Frame: after 6 months
|
after 6 months
|
|
|
Assessment of metabolic effect on a 4-point scale
Time Frame: after 6 months
|
after 6 months
|
|
|
Change from Baseline in laboratory parameters
Time Frame: Baseline, after 6 months
|
Metabolic parameters - Triglyceride, total cholesterol, blood glucose and HbA1c
|
Baseline, after 6 months
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Hypertension
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Antihypertensive Agents
- Natriuretic Agents
- Membrane Transport Modulators
- Diuretics
- Angiotensin II Type 1 Receptor Blockers
- Angiotensin Receptor Antagonists
- Sodium Chloride Symporter Inhibitors
- Telmisartan
- Telmisartan, hydrochlorothiazide drug combination
Other Study ID Numbers
Other Study ID Numbers
- 502.505
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.